<DOC>
	<DOCNO>NCT01254708</DOCNO>
	<brief_summary>Lung transplant recipient high rate Invasive Aspergillus ( IA ) infection among solid organ transplant recipient . The important risk factor development IA ( associate disease death ) colonization organism respiratory tract . Azoles use prevent development IA . Puffers contain antifungal medication use treat lung without need worry medication interaction &amp; side-effects blood . An example aerosolize amphotericin B . Its use limited patient ' tolerate medication may cause cough , nausea &amp; contraction air pathway . The lipid preparation well tolerate longer dose interval inhale amphotericin B . The investigator propose pilot study determine long-term safety inhale AmBisome administration drug generate preliminary data effectiveness drug prevent aspergillus colonization .</brief_summary>
	<brief_title>Safety Efficacy Study Inhaled AmBisome Prevention Aspergillus Colonization Lung Transplant Recipients</brief_title>
	<detailed_description>In pilot study , main aim : 1 . To determine safety weekly Inhaled AmBisome prophylaxis prevent development Aspergillus colonization lung transplant recipient one year prophylaxis . 2 . To generate preliminary data efficacy Inhaled AmBisome ( Astellas ) load dose ( 1mg/kg/day four day ) initially follow q weekly dosage complete 1 year lung transplant recipient compare prophylaxis assess rate fungal colonization/infections group .</detailed_description>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<criteria>1 . Single double lung transplant recipient least one year transplantation . 2 . Age &gt; 18yrs age 3 . Able understand complete inform consent . 1 . Pregnant woman woman capable bearing child , perform urine pregnancy test . 2 . Nursing mother . 3 . Subjects hypersensitivity Amphotericin deoxycholate liposomal Amphotericin . 4 . Subjects past history bronchospasm associate aerosol drug use . 5 . Subjects active bacterial viral infection define current use nonprophylactic antibiotic antiviral medication . 6 . Subjects treat cytolytic medication ( Campath /Thymoglobulin ) within last month . 7 . Subjects FEV1 &lt; 30 % Predicted FVC % &lt; 30 % . 8 . Subjects require supplemental oxygen . 9 . Receipt Inhaled IV Amphotericin B within last 30 day . 10 . Subjects know fungal infection per MSG Criteria therapy antifungal drug diagnose day bronchoscopy . 11 . Current use azoles active mold ( Voriconazole , itraconazole , posaconazole ) prophylaxis . 12 . Serum creatinine &gt; 150 mmol/L day clinic visit . 13 . Liver enzymes ALT/ AST/ Alkphos great two time upper limit normal . 14 . Concurrent intravenous aminoglycoside use . 15 . Subjects fever &gt; 38.2Â°C . 16 . Subjects mechanical ventilation . 17 . Expected survival le 6 month . 18 . Retransplants heart/lung transplant patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>